Label: ZEMAIRA- alpha-1-proteinase inhibitor human kit kit

  • NDC Code(s): 57516-101-02, 57516-102-01, 57516-103-20, 57516-110-02, view more
    57516-111-01, 57516-112-20, 57516-113-02, 57516-114-01, 57516-115-20
  • Packager: Fisher Clinical Services Inc.
  • Category: PLASMA DERIVATIVE
  • DEA Schedule: None
  • Marketing Status: Biologic Licensing Application

Drug Label Information

Updated March 31, 2025

If you are a consumer or patient please visit this version.

  • PRINCIPAL DISPLAY PANEL

    Zemaira 1000mg carton

  • PRINCIPAL DISPLAY PANEL

    Zemaira 4000mg

  • PRINCIPAL DISPLAY PANEL

    Zemaira 500mg

  • INGREDIENTS AND APPEARANCE
    ZEMAIRA 
    alpha-1-proteinase inhibitor human kit kit
    Product Information
    Product TypePLASMA DERIVATIVEItem Code (Source)NDC:57516-113
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:57516-113-021 in 1 CARTON
    Quantity of Parts
    Part #Package QuantityTotal Product Quantity
    Part 11 VIAL, SINGLE-DOSE 95 mL
    Part 21 VIAL, SINGLE-DOSE 95 mL
    Part 1 of 2
    ALPHA-1-PROTEINASE INHIBITOR HUMAN 
    alpha-1-proteinase inhibitor human injection, powder, lyophilized, for solution
    Product Information
    Item Code (Source)NDC:57516-114
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    .ALPHA.1-PROTEINASE INHIBITOR HUMAN (UNII: F43I396OIS) (.ALPHA.1-PROTEINASE INHIBITOR HUMAN - UNII:F43I396OIS) .ALPHA.1-PROTEINASE INHIBITOR HUMAN5000 mg  in 95 mL
    Inactive Ingredients
    Ingredient NameStrength
    MANNITOL (UNII: 3OWL53L36A)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:57516-114-0195 mL in 1 VIAL, SINGLE-DOSE; Type 6: Drug/Biologic Combination
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    BLABLA12507807/31/2023
    Part 2 of 2
    DILUENT 
    water injection injection
    Product Information
    Item Code (Source)NDC:57516-115
    Route of AdministrationINTRAVENOUS
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:57516-115-2095 mL in 1 VIAL, SINGLE-DOSE; Type 6: Drug/Biologic Combination
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    BLABLA12507804/24/2019
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    BLABLA12507807/31/2023
    ZEMAIRA 
    alpha-1-proteinase inhibitor human kit kit
    Product Information
    Product TypePLASMA DERIVATIVEItem Code (Source)NDC:57516-110
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:57516-110-021 in 1 CARTON
    Quantity of Parts
    Part #Package QuantityTotal Product Quantity
    Part 11 VIAL, SINGLE-DOSE 76 mL
    Part 21 VIAL, SINGLE-DOSE 76 mL
    Part 1 of 2
    ALPHA-1-PROTEINASE INHIBITOR HUMAN 
    alpha-1-proteinase inhibitor human injection, powder, lyophilized, for solution
    Product Information
    Item Code (Source)NDC:57516-111
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    .ALPHA.1-PROTEINASE INHIBITOR HUMAN (UNII: F43I396OIS) (.ALPHA.1-PROTEINASE INHIBITOR HUMAN - UNII:F43I396OIS) .ALPHA.1-PROTEINASE INHIBITOR HUMAN4000 mg  in 76 mL
    Inactive Ingredients
    Ingredient NameStrength
    MANNITOL (UNII: 3OWL53L36A)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:57516-111-0176 mL in 1 VIAL, SINGLE-DOSE; Type 6: Drug/Biologic Combination
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    BLABLA12507807/31/2023
    Part 2 of 2
    DILUENT 
    water injection injection
    Product Information
    Item Code (Source)NDC:57516-112
    Route of AdministrationINTRAVENOUS
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:57516-112-2076 mL in 1 VIAL, SINGLE-DOSE; Type 6: Drug/Biologic Combination
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    BLABLA12507807/31/2023
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    BLABLA12507807/31/2023
    ZEMAIRA 
    alpha-1-proteinase inhibitor human kit kit
    Product Information
    Product TypePLASMA DERIVATIVEItem Code (Source)NDC:57516-101
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:57516-101-021 in 1 CARTON
    Quantity of Parts
    Part #Package QuantityTotal Product Quantity
    Part 11 VIAL, SINGLE-DOSE 20 mL
    Part 21 VIAL, SINGLE-DOSE 20 mL
    Part 1 of 2
    ALPHA-1-PROTEINASE INHIBITOR HUMAN 
    alpha-1-proteinase inhibitor human injection, powder, lyophilized, for solution
    Product Information
    Item Code (Source)NDC:57516-102
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    .ALPHA.1-PROTEINASE INHIBITOR HUMAN (UNII: F43I396OIS) (.ALPHA.1-PROTEINASE INHIBITOR HUMAN - UNII:F43I396OIS) .ALPHA.1-PROTEINASE INHIBITOR HUMAN1000 mg  in 20 mL
    Inactive Ingredients
    Ingredient NameStrength
    MANNITOL (UNII: 3OWL53L36A) 525 mg  in 20 mL
    SODIUM PHOSPHATE (UNII: SE337SVY37) 47 mg  in 20 mL
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    SODIUM CHLORIDE (UNII: 451W47IQ8X) 44 mg  in 20 mL
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:57516-102-0120 mL in 1 VIAL, SINGLE-DOSE; Type 6: Drug/Biologic Combination
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    BLABLA12507802/22/2022
    Part 2 of 2
    DILUENT 
    water injection injection
    Product Information
    Item Code (Source)NDC:57516-103
    Route of AdministrationINTRAVENOUS
    Inactive Ingredients
    Ingredient NameStrength
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:57516-103-2020 mL in 1 VIAL, SINGLE-DOSE; Type 6: Drug/Biologic Combination
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    BLABLA12507802/22/2022
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    BLABLA12507802/22/2022
    Labeler - Fisher Clinical Services Inc. (199879800)
    Registrant - Fisher Clinical Services (079957165)
    Establishment
    NameAddressID/FEIBusiness Operations
    Fisher Clinical Services Inc.199879800manufacture(57516-101, 57516-110, 57516-113) , pack(57516-101, 57516-110, 57516-113) , label(57516-110, 57516-101, 57516-113)